Overcoming the multi-drug resistant phenotype by targeting ABCB1 in cancer cells at the functional or transcriptional level is a constant topic of anti-cancer research (6, 7), which will allow to re-use anthracyclines, like doxorubicin, as highly effective anti-cancer drugs in CRC (8, 9). This evidence concerns the gene ABCB1 and cancer.